Keywords Chemotherapy induced cardiotox...

Chemotherapy induced cardiotoxicity
Giuseppina Novo, Ciro Santoro, Girolamo Manno, Daniela Di Lisi, Roberta Esposito, Giulia Elena Mandoli, Vincenzo Evola, Maria Concetta Pastore, Simona Sperlongano, Antonello D'Andrea, Matteo Cameli, Maurizio Galderisi
In recent years, the survival of patients with cancer has improved thanks to advances in antineoplastic therapeutic protocols. This has led to an increasing burden of cardiovascular complications related to cancer treatment. Therefore, a new branch of cardiology has been created, "cardio-oncology," with the aims of preventing cardiovascular complications related to antineoplastic treatment, achieving early diagnosis and treatment of any complications, and allowing completion of the expected antineoplastic treatment...
November 19, 2020: Journal of the American Society of Echocardiography
Francisco Teixeira da Silva, Rita Morais Passos, Alexandra Esteves, José Carvalho, Manuel Ferreira
Cardiotoxicity is a relevant side effect of cancer therapy that leads to increased patient morbidity and mortality. It is fundamental to understand and remember it as a cause of disease since accurate and timely diagnosis is crucial. We present the case of a patient who developed chemotherapy-associated cardiac dysfunction after receiving treatment for a diffuse large B-cell lymphoma. Clinical history, echocardiography, and differential diagnosis led us to attribute her condition to heart failure (HF) due to early doxorubicin-induced cardiomyopathy...
October 19, 2020: Curēus
Toshio Kinoshita, Hitomi Yuzawa, Kazuhiko Natori, Ryo Wada, Shintaro Yao, Kensuke Yano, Katsuya Akitsu, Hideki Koike, Masaya Shinohara, Tadashi Fujino, Hideaki Shimada, Takanori Ikeda
BACKGROUND: Dealing with chemotherapy-related cardiac dysfunction (CTRCD) remains a significant problem complicated by the difficulty in early detection of cardiotoxicity. Electrocardiogram (ECG) is expected to be the most realistic methodology due to lower cost-performance and non-invasiveness. We investigated the long-term visual fluctuations in the ECG waveforms in patients with chronic doxorubicin (DOX)-induced cardiotoxicity to identify ECG indices for the early detection of cardiotoxicity...
November 16, 2020: Journal of Cardiology
Dragoș-Mihai Romitan, Dan Rădulescu, Ioana Berindan-Neagoe, Laurențiu Stoicescu, Alin Grosu, Liliana Rădulescu, Diana Gulei, Tudor-Eliade Ciuleanu
Cardiology and oncology are two fields dedicated to the study of various types of oncological and cardiac diseases, but when they collide, a new specialty is born, i.e., cardio-oncology. Continuous research on cancer therapy has brought into the clinic novel therapeutics that have significantly improved patient survival. However, these therapies have also been associated with adverse effects that can impede the proper management of oncological patients through the necessity of drug discontinuation due to life-threatening or long-term morbidity risks...
November 12, 2020: Biomedicines
Suyeewin Thiha, Chris A Robert, Abdul Rehman Z Zaidi
Cardiotoxicity can reduce the heart's function temporarily and is most commonly caused by radiation, immune reactions, and certain medications. Using a left ventricular assist device (LVAD) as a bridging therapy while waiting for cardiac recovery has been popular lately in patients who have a reduced ejection fraction after significant cardiac injury. Here we analyze the use of LVAD as a bridging therapy in three cases with chemotherapy-induced cardiotoxicity, acute myocarditis, and postpartum cardiac failure...
October 12, 2020: Curēus
Anton E Andersson, Barbro Linderholm, Daniel Giglio
BACKGROUND: Overall survival has improved significantly in patients with human epidermal growth receptor 2 (HER2)-positive breast cancer due to the use of the monoclonal antibody trastuzumab blocking HER2. However, patients may develop trastuzumab-induced cardiotoxicity (TIC) leading to congestive heart failure. Here we assessed whether analysing NT-proBNP and assessment of electrocardiography (ECG) could detect TIC during trastuzumab therapy. METHODS: One hundred thirty-six patients undergoing adjuvant, neoadjuvant or palliative chemotherapy and HER2 blockade for HER2-positive breast cancer were prospectively assessed with echocardiography, ECG and N-terminal - pro hormone B-type natriuretic peptide (NT-proBNP) testing at baseline and at 6 and 12 months of trastuzumab therapy...
November 16, 2020: Acta Oncologica
Raluca Maria Pop, Ioana Corina Bocsan, Anca Dana Buzoianu, Veronica Sanda Chedea, Sonia Ancuța Socaci, Michela Pecoraro, Ada Popolo
Natural products black cumin- Nigella sativa ( N. sativa ) and wild garlic- Allium ursinum (AU) are known for their potential role in reducing cardiovascular risk factors, including antracycline chemotherapy. Therefore, this study investigates the effect of N. sativa and AU water and methanolic extracts in a cellular model of doxorubicin (doxo)-induced cardiotoxicity. The extracts were characterized using Ultraviolet-visible (UV-VIS) spectroscopy, Fourier-transform infrared (FT-IR) spectroscopy, Liquid Chromatography coupled with Mass Spectrometry (LC-MS) and Gas Chromatography coupled with Mass Spectrometry (GC-MS) techniques...
November 11, 2020: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
Alexa N Carrera, Marianne K O Grant, Beshay N Zordoky
Cardiovascular complications have been frequently reported in cancer patients and survivors, mainly because of various cardiotoxic cancer treatments. Despite the known cardiovascular toxic effects of these treatments, they are still clinically used because of their effectiveness as anti-cancer agents. In this review, we discuss the growing body of evidence suggesting that inhibition of the cytochrome P450 1B1 enzyme (CYP1B1) can be a promising therapeutic strategy that has the potential to prevent cancer treatment-induced cardiovascular complications without reducing their anti-cancer effects...
November 13, 2020: Clinical Science (1979-)
Hongbo Men, He Cai, Quanli Cheng, Wenqian Zhou, Xiang Wang, Shan Huang, Yang Zheng, Lu Cai
Cardiovascular disease (CVD) remains the leading cause of mortality globally, so further investigation is required to identify its underlying mechanisms and potential targets for its prevention. The transcription factor p53 functions as a gatekeeper, regulating a myriad of genes to maintain normal cell functions. It has received a great deal of research attention as a tumor suppressor. In the past three decades, evidence has also shown a regulatory role for p53 in the heart. Basal p53 is essential for embryonic cardiac development; it is also necessary to maintain normal heart architecture and physiological function...
November 11, 2020: Cellular and Molecular Life Sciences: CMLS
Iva N Dimitrova
5-Fluorouracil (5-FU), a pyrimidine analogue, is widely used in different chemotherapy regimens with established indications for the treatment of gastrointestinal, breast, head, and neck tumors. Various prospective studies including randomized controlled trials and retrospective reviews have shown a wide range of reported incidence of cardiotoxicity related to 5-FU use. This incidence is dependent on drug regimen, doses, concomitant therapy, patients' clinical characteristics, and risk factors. Herein, we present a clinical case of coronary vasospasm mimicking ST-elevation myocardial infarction during a 5-FU infusion for salivary gland cancer...
October 10, 2020: Curēus
Yucong Xue, Mengying Li, Yurun Xue, Weiyue Jin, Xue Han, Jianping Zhang, Xi Chu, Ziliang Li, Li Chu
Arsenic trioxide (ATO) is a frontline chemotherapy drug used in the therapy of acute promyelocytic leukemia. However, the clinical use of ATO is hindered by its cardiotoxicity. The present study aimed to observe the potential effects and underlying mechanisms of tannic acid (TA) against ATO‑induced cardiotoxicity. Male rats were intraperitoneally injected with ATO (5 mg/kg/day) to induce cardiotoxicity. TA (20 and 40 mg/kg/day) was administered to evaluate its cardioprotective efficacy against ATO‑induced heart injury in rats...
October 11, 2020: Molecular Medicine Reports
Giorgio Minotti, Pierantonio Menna, Massimiliano Camilli, Emanuela Salvatorelli, Giorgio Reggiardo
Diastolic dysfunction (DD) is an early manifestation of cancer drugs cardiotoxicity. Anthracyclines are considered as more cardiotoxic than other chemotherapeutics but previous studies have shown that both anthracycline-based and nonanthracycline chemotherapy can cause an early DD, detected one week after the end of chemotherapy. Here we characterized if DD also occurred in a delayed form, detected six months after chemotherapy. Sixty-seven comorbidity-free patients were examined. DD was diagnosed by echocardiography and cardiac biomarkers...
November 9, 2020: Journal of Pharmacology and Experimental Therapeutics
Rui Liu, Dong Li, Fangxu Sun, Antonio Rampoldi, Joshua T Maxwell, Ronghu Wu, Peter Fischbach, Sharon M Castellino, Yuhong Du, Haian Fu, Anant Mandawat, Chunhui Xu
BACKGROUND: Treatment-induced cardiotoxicity is a leading noncancer-related cause of acute and late onset morbidity and mortality in cancer patients on antineoplastic drugs such as melphalan-increasing clinical case reports have documented that it could induce cardiotoxicity including severe arrhythmias and heart failure. As the mechanism by which melphalan impairs cardiac cells remains poorly understood, here, we aimed to use cardiomyocytes derived from human induced pluripotent stem cells (hiPSC-CMs) to investigate the cellular and molecular mechanisms of melphalan-induced cardiotoxicity...
November 5, 2020: Stem Cell Research & Therapy
Wael M Aboulthana, Ram K Sahu, Mahmoud H Saleh
Cancer is considered as one of the most common leading causes of death worldwide. In developed countries, the lifestyles including poor diet, smoking, reproductive changes and physical inactivity are known to increase the susceptibility to cancer diseases. Moreover, the exposure to ionizing radiation, carcinomas chemicals, certain metals and some other specific substances even at low concentrations increase the risk to cancer diseases. Cancer progression is often associated with irregularities in cell cycle and these alterations induced mainly as a result of oxidative stress and generation of the reactive oxygen species (ROS)...
November 5, 2020: Anti-cancer Agents in Medicinal Chemistry
Ryan N Montalvo, Vivian Doerr, Oh Sung Kwon, Erin E Talbert, Jeung-Ki Yoo, Moon-Hyon Hwang, Branden L Nguyen, Demetra D Christou, Andreas N Kavazis, Ashley J Smuder
Doxorubicin (DOX) is a highly effective chemotherapeutic agent used in the treatment of various cancer types. Nevertheless, it is well known that DOX promotes the development of severe cardiovascular complications. Therefore, investigation into the underlying mechanisms that drive DOX-induced cardiotoxicity is necessary to develop therapeutic countermeasures. In this regard, autophagy is a complex catabolic process that is increased in the heart following DOX exposure. However, conflicting evidence exists regarding the role of autophagy dysregulation in the etiology of DOX-induced cardiac dysfunction...
October 30, 2020: International Journal of Molecular Sciences
N V Tursunova, M G Klinnikova, O A Babenko, E L Lushnikova
The manifestation of the side cardiotoxic effect of anthracycline antibiotics limits their use in the treatment of malignant processes in some patients. The review analyzes the main causes of the susceptibility of cardiomyocytes to the damaging effect of anthracyclines, primarily associated with an increase in the processes of free radical oxidation. Currently, research is widely carried out to find ways to reduce anthracycline cardiotoxicity, in particular, the use of cardioprotective agents in the complex treatment of tumors...
September 2020: Biomedit︠s︡inskai︠a︡ Khimii︠a︡
Yan Lin, Jianfeng Wang, Min Xu, Chun Qiu, Peng Xu, Limei Shang, Bai He, Fei Wang, Yanhua Yue, Yanting Guo, Feng Li, Weimin Dong, Xiaobao Xie, Yuetao Wang, Weiying Gu
Anthracycline chemotherapy is commonly used in the treatment of diffuse large B-cell lymphoma (DLBCL). Treatment-related cardiotoxicity (TRC) is defined as when the patient is identified to have one of the following clinical manifestations: Symptomatic heart failure, cardiac death, arrhythmia, infarction, a decrease in left ventricular ejection fraction (LVEF) of >15% from baseline or a decrease in LVEF of >10 to <50%. TRC may induce severe cardiac failure or cardiac arrhythmia as the main cause of death...
December 2020: Oncology Letters
Wei Wang, Qin Fang, Zhihao Zhang, Daowen Wang, Lujin Wu, Yan Wang
Doxorubicin (DOX), a chemotherapeutic drug widely used in the clinical setting, is known to cause serious cardiotoxicity and greatly reduces the survival rate as well as quality of life of patients receiving chemotherapy. Peroxisome proliferation activated receptor α (PPARα) is a type of ligand activated receptor of the nuclear hormone receptor family that regulates multiple gene expression. Several studies have shown that PPARα has anti-apoptotic and cardio-protective effects. However, its role in DOX-induced cardiotoxicity is rarely reported...
2020: Frontiers in Pharmacology
Lei Zhuang, Wenzheng Xia, Didi Chen, Yijia Ye, Tingting Hu, Shiting Li, Meng Hou
BACKGROUND: The chemotherapy drug doxorubicin (Dox) is widely used for treating a variety of cancers. However, its high cardiotoxicity hampered its clinical use. Exosomes derived from stem cells showed a therapeutic effect against Dox-induced cardiomyopathy (DIC). Previous studies reported that exosomes derived from mesenchymal stem cells (MSCs) pretreated with macrophage migration inhibitory factor (MIF) (exosomeMIF ) showed a cardioprotective effect through modulating long noncoding RNAs/microRNAs (lncRNAs/miRs)...
October 31, 2020: Journal of Nanobiotechnology
Muhammad Wasif Saif
5-Fluorouracil (5-FU) remains to be the backbone of chemotherapy regimens approved for treatment of colorectal cancer and other gastrointestinal cancers and breast cancer. The incidence of cardiotoxicity associated with 5-FU ranges from 1.5-18%. Previous studies also concluded that rechallenging a patient with previous 5-FU cardiotoxicity with either lower dose or another mode of administration could result in repeat of cardiac complication in up to 45% of patients. Nearly 13% of patients died upon re-exposure to 5-FU...
2020: OncoTargets and Therapy
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"